2016欧洲血脂异常管理指南更新要点ppt课件.pptxVIP

2016 欧洲心脏病学会 欧洲动脉粥样硬化学会血脂异常管理指南 解读 2016年8月 ESC于意大利首都罗马召开2016年年会 期间发布了备受瞩目的 《2016欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南》 坚持总体的心血管风险评估 扩大风险评估及极高危人群 范畴 PART ONE 核心策略 SCORE评分 《2016 年指南》继续强调评价患者整体心血管风险、强调生活方式改良是管理血脂异常的核心策略 对于年龄＞40岁的 无心血管病、糖尿病、慢性肾病或家族性高胆固醇血症证据的无症状成年人，建议应用SCORE评分等风险评估系统评估总体心血管风险 SCORE 评分 1.Based on large, representative European cohort datasets. 2.SCORE is intended to facilitate risk estimation apparently healthy persons with no documented CVD. 3. Persons with documented CVD、 type 1 or type 2 diabetes、 very high levels of individual risk factors、chronic kidney disease（CKD）are automatically at very high or high total CV risk. No risk estimation models are needed for them they all need active management of all risk factors. SCORE 评分 4. The SCORE system estimates the 10-year cumulative risk of a first fatal atherosclerotic event, whether heart attack, stroke or other occlusive arterial disease, including sudden cardiac death. 5. The SCORE data indicate that the total CVD event risk is about three times higher than the risk of fatal CVD for men, so that a SCORE risk of 5% translates into a CVD risk of 15% of total (fatal + non-fatal) hard CVD endpoints the multiplier is 4 in women and lower in older persons. How to use the risk estimation charts ‘Low risk’ are based on age-adjusted 2012 CVD mortality rates(225/100 000 in men and ,175/100 000 in women) the low-risk charts should be considered for use in Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, The Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. How to use the risk estimation charts 3. ≥450/100 000 for men or ≥350/100 000 for women 4.Albania, Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kazakhstan, Kyrgyzstan, Latvia, FYR Macedonia, Republic of Moldova, Russian Federation, Syrian Arab Republic, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Bosn